Abstract Listings 2024

Purpose

To report a series of 3 cases of bisphosphonate-induced orbital inflammation, together with a brief review of the literature and a proposed management algorithm.

Methods

Introduction:
Bisphosphonates are a class of drugs widely used in the treatment of osteoporosis. We observed 3 cases of orbital inflammation following zoledronic acid infusion between 2020 and 2023 at the University Hospital of Nantes (France). This is a complication described in Vidal (“ophthalmological side effect: orbital inflammation, uncommon”), which seems to be poorly understood and is worth mentioning.

Materials and Methods:
Description of a series of 3 cases (3 men) accompanied by iconographies (photographs and MRI-CT scans) accompanied by a review of the literature. About forty cases are described in the literature.

Results

Results: (to be completed as not all data have been collected)
-Presentation of 3 cases (2 bilateral and 1 unilateral) treated at the Nantes University Hospital (France), accompanied by photographs and imaging (MRI, CT).
-Review of the literature, including about thirty articles on PubMed, reporting about forty cases. The clinical presentation is very similar to that of idiopathic orbital inflammation, mostly unilateral (89%), and occurs on average within 72 hours of zoledronic acid infusion. Clinical signs included exophthalmos (56%), oculomotor limitation (65%) and chemosis (79%). Progression was rapidly favourable with intravenous or oral corticosteroids, with ad integrum recovery in the majority of cases.

Conclusion

Discussion:
This topic serves as a reminder of the importance of both questioning and reporting adverse reactions in pharmacovigilance. A suggested management algorithm is provided for discussion.

Additional Authors

↑ Back to top